200 related articles for article (PubMed ID: 12759881)
1. Regulation of skeletal muscle morphology in type 2 diabetic subjects by troglitazone and metformin: relationship to glucose disposal.
Mathieu-Costello O; Kong A; Ciaraldi TP; Cui L; Ju Y; Chu N; Kim D; Mudaliar S; Henry RR
Metabolism; 2003 May; 52(5):540-6. PubMed ID: 12759881
[TBL] [Abstract][Full Text] [Related]
2. Troglitazone but not metformin restores insulin-stimulated phosphoinositide 3-kinase activity and increases p110beta protein levels in skeletal muscle of type 2 diabetic subjects.
Kim YB; Ciaraldi TP; Kong A; Kim D; Chu N; Mohideen P; Mudaliar S; Henry RR; Kahn BB
Diabetes; 2002 Feb; 51(2):443-8. PubMed ID: 11812753
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.
Inzucchi SE; Maggs DG; Spollett GR; Page SL; Rife FS; Walton V; Shulman GI
N Engl J Med; 1998 Mar; 338(13):867-72. PubMed ID: 9516221
[TBL] [Abstract][Full Text] [Related]
4. Thiazolidinediones upregulate impaired fatty acid uptake in skeletal muscle of type 2 diabetic subjects.
Wilmsen HM; Ciaraldi TP; Carter L; Reehman N; Mudaliar SR; Henry RR
Am J Physiol Endocrinol Metab; 2003 Aug; 285(2):E354-62. PubMed ID: 12700163
[TBL] [Abstract][Full Text] [Related]
5. Effects of pioglitazone and metformin on intracellular lipid content in liver and skeletal muscle of individuals with type 2 diabetes mellitus.
Teranishi T; Ohara T; Maeda K; Zenibayashi M; Kouyama K; Hirota Y; Kawamitsu H; Fujii M; Sugimura K; Kasuga M
Metabolism; 2007 Oct; 56(10):1418-24. PubMed ID: 17884455
[TBL] [Abstract][Full Text] [Related]
6. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; Palumbo I; D'Angelo A; Cicero AF
Metabolism; 2009 Aug; 58(8):1059-66. PubMed ID: 19394976
[TBL] [Abstract][Full Text] [Related]
7. Regulation of glucose transport and insulin signaling by troglitazone or metformin in adipose tissue of type 2 diabetic subjects.
Ciaraldi TP; Kong AP; Chu NV; Kim DD; Baxi S; Loviscach M; Plodkowski R; Reitz R; Caulfield M; Mudaliar S; Henry RR
Diabetes; 2002 Jan; 51(1):30-6. PubMed ID: 11756319
[TBL] [Abstract][Full Text] [Related]
8. Long-term cardiovascular effects of insulin sensitizer troglitazone on non-diabetic individuals with insulin resistance: double blind, prospective randomized study.
Stakos DA; Schuster DP; Sparks EA; Wooley CF; Osei K; Boudoulas H
J Cardiol; 2003 Apr; 41(4):183-90. PubMed ID: 12728539
[TBL] [Abstract][Full Text] [Related]
9. Troglitazone improves whole-body insulin resistance and skeletal muscle glucose use in type II diabetic patients.
Yokoyama I; Yonekura K; Moritan T; Tateno M; Momose T; Ohtomo K; Inoue Y; Nagai R
J Nucl Med; 2001 Jul; 42(7):1005-10. PubMed ID: 11438619
[TBL] [Abstract][Full Text] [Related]
10. Increased malonyl-CoA levels in muscle from obese and type 2 diabetic subjects lead to decreased fatty acid oxidation and increased lipogenesis; thiazolidinedione treatment reverses these defects.
Bandyopadhyay GK; Yu JG; Ofrecio J; Olefsky JM
Diabetes; 2006 Aug; 55(8):2277-85. PubMed ID: 16873691
[TBL] [Abstract][Full Text] [Related]
11. Troglitazone therapy improves endothelial function to near normal levels in women with polycystic ovary syndrome.
Paradisi G; Steinberg HO; Shepard MK; Hook G; Baron AD
J Clin Endocrinol Metab; 2003 Feb; 88(2):576-80. PubMed ID: 12574183
[TBL] [Abstract][Full Text] [Related]
12. Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: a novel target of thiazolidinediones.
Varo N; Vicent D; Libby P; Nuzzo R; Calle-Pascual AL; Bernal MR; Fernández-Cruz A; Veves A; Jarolim P; Varo JJ; Goldfine A; Horton E; Schönbeck U
Circulation; 2003 Jun; 107(21):2664-9. PubMed ID: 12742991
[TBL] [Abstract][Full Text] [Related]
13. Skeletal muscle capillary responses to insulin are abnormal in late-stage diabetes and are restored by angiotensin-converting enzyme inhibition.
Clerk LH; Vincent MA; Barrett EJ; Lankford MF; Lindner JR
Am J Physiol Endocrinol Metab; 2007 Dec; 293(6):E1804-9. PubMed ID: 17911341
[TBL] [Abstract][Full Text] [Related]
14. A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients.
Yu JG; Kruszynska YT; Mulford MI; Olefsky JM
Diabetes; 1999 Dec; 48(12):2414-21. PubMed ID: 10580431
[TBL] [Abstract][Full Text] [Related]
15. Effects of pioglitazone and metformin on plasma adiponectin in newly detected type 2 diabetes mellitus.
Sharma PK; Bhansali A; Sialy R; Malhotra S; Pandhi P
Clin Endocrinol (Oxf); 2006 Dec; 65(6):722-8. PubMed ID: 17121522
[TBL] [Abstract][Full Text] [Related]
16. New oral therapies for type 2 diabetes.
Purnell JQ; Hirsch IB
Am Fam Physician; 1997 Nov; 56(7):1835-42. PubMed ID: 9371013
[TBL] [Abstract][Full Text] [Related]
17. Adiponectin and its response to thiazolidinediones are associated with insulin-mediated glucose metabolism in type 2 diabetic patients and their first-degree relatives.
Hulstrøm V; Højlund K; Vinten J; Beck-Nielsen H; Levin K
Diabetes Obes Metab; 2008 Nov; 10(11):1019-28. PubMed ID: 18284435
[TBL] [Abstract][Full Text] [Related]
18. The effect of pioglitazone as add-on therapy to metformin or sulphonylurea compared to a fixed-dose combination of metformin and glibenclamide on diabetic dyslipidaemia.
Comaschi M; Corsi A; Di Pietro C; Bellatreccia A; Mariz S;
Nutr Metab Cardiovasc Dis; 2008 Jun; 18(5):373-9. PubMed ID: 17919894
[TBL] [Abstract][Full Text] [Related]
19. In vivo kinetics of 123 iodine-labelled insulin in skeletal muscle of patients with type 2 diabetes. Effect of metformin.
Valensi P; Behar A; Cohen-Boulakia F; Valensi J; Wiernsperger N; Attali JR
Diabetes Metab; 2002 Apr; 28(2):95-103. PubMed ID: 11976561
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy using metformin or thiazolidinediones and insulin in the treatment of diabetes mellitus.
Strowig SM; Raskin P
Diabetes Obes Metab; 2005 Nov; 7(6):633-41. PubMed ID: 16219007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
